Inserm U646, Angers F-49100, France.
Int J Pharm. 2011 Apr 4;407(1-2):1-11. doi: 10.1016/j.ijpharm.2011.01.027. Epub 2011 Jan 21.
Drug delivery via biodegradable microparticles benefits from both the protection of the encapsulated drug from hazardous conditions and the controlled release of the encapsulated drug, thereby reducing the administration frequency and improving patient compliance. Microsphere-size particle distribution is considered as being an important factor that affects the choice of the administration route and the drug-release rate. Significant research efforts have been directed towards the production of monodispersed "designer" particles. Amongst various techniques, some have been examined from lab-scale to industrial-scale. This review provides a global overview of monodispersed microparticle production methods and then focuses on recent processes being used to produce biodegradable microparticles applied in the pharmaceutical field. Further discussion about the choice of process according to the microparticle objectives of use is suggested.
药物传递通过可生物降解的微球得益于被包裹药物免受危险条件的保护和被包裹药物的控制释放，从而减少了给药频率并提高了患者的顺应性。微球大小的颗粒分布被认为是影响给药途径和药物释放速率选择的重要因素。人们已经投入了大量的研究精力来生产单分散的“设计”颗粒。在各种技术中，已经有一些从实验室规模到工业规模进行了研究。本综述提供了单分散微粒子生产方法的全球概述，然后重点介绍了最近用于生产应用于制药领域的可生物降解微球的工艺。进一步讨论了根据微球使用目标选择工艺的问题。
